- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03920267
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
December 19, 2023 updated by: Bristol-Myers Squibb
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
261
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Caba, Argentina, 1111
- Local Institution - 0100
-
Cordoba, Argentina, X5004FHP
- Local Institution - 0122
-
Mendoza, Argentina, 5500
- Local Institution - 0095
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1430
- Clinica Adventista Belgrano
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1046
- Local Institution - 0125
-
-
Santa FE
-
Rosario, Santa FE, Argentina, 2000
- Local Institution - 0098
-
-
Tucuman
-
San Miguel De Tucum, Tucuman, Argentina, T4000AXL
- Centro Medico Privado de Reumatologia
-
-
-
-
-
Sao Paulo, Brazil, 01228-200
- Local Institution - 0105
-
-
Bahia
-
Salvador, Bahia, Brazil, 40150150
- Local Institution - 0116
-
-
Goias
-
Goiߡ, Goias, Brazil, 74110-120
- Local Institution - 0118
-
-
Minas Gerais
-
Juiz de Fora, Minas Gerais, Brazil, 36010-570
- Local Institution - 0106
-
-
Parana
-
Curitiba, Parana, Brazil, 80030-110
- Local Institution - 0120
-
-
RIO Grande DO SUL
-
Porto Alegre, RIO Grande DO SUL, Brazil, 90480-000
- Local Institution - 0107
-
-
SAO Paulo
-
Sao Bernardo do Campo, SAO Paulo, Brazil, 09715-090
- Local Institution - 0111
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- University of Calgary
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Local Institution - 0136
-
-
-
-
-
Barranquilla, Colombia
- Local Institution - 0108
-
Bogot, Colombia, 110221
- Local Institution - 0101
-
Chia, Colombia, 250001
- Local Institution - 0103
-
Zipaquira, Colombia, 250252
- Local Institution - 0096
-
-
-
-
-
Debrecen, Hungary, 4032
- Local Institution - 0039
-
Gyula, Hungary, 5700
- Local Institution - 0038
-
Szeged, Hungary, 6725
- Local Institution - 0045
-
-
-
-
-
Tokyo, Japan, 162-8655
- Local Institution - 0066
-
Tokyo, Japan, 173-8610
- Local Institution - 0093
-
Tokyo, Japan, 113-8431
- Local Institution - 0078
-
-
Chiba
-
Chiba-shi, Chiba, Japan, 260-8712
- National Hospital Organization Chibahigashi National Hospital
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japan, 807-8556
- Local Institution - 0092
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Hokkaido University Hospital
-
Sapporo-Shi, Hokkaido, Japan, 060-8604
- Sapporo City General Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japan, 9808574
- Local Institution - 0063
-
-
Tochigi
-
Shimotsuke-city, Tochigi, Japan, 329-0498
- Local Institution - 0069
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-8560
- Local Institution - 0065
-
-
-
-
-
Seoul, Korea, Republic of, 110-744
- Local Institution
-
Suwon, Korea, Republic of, 16499
- Local Institution - 0053
-
-
-
-
-
San Luis Potosi, Mexico, 78213
- Local Institution - 0082
-
-
Distrito Federal
-
Mexico City, Distrito Federal, Mexico, 06760
- Local Institution - 0087
-
-
Guanajuato
-
Leon, Guanajuato, Mexico, 37000
- Local Institution - 0080
-
Leon, Guanajuato, Mexico, 37160
- Centro de Investigacion Farmacologica del Bajio
-
-
Jalisco
-
Zapopan, Jalisco, Mexico, 45070
- Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V.
-
-
Nuevo LEON
-
Monterrey, Nuevo LEON, Mexico, 64000
- Accelerium Clinical Research
-
-
-
-
-
Bydgoszcz, Poland, 85-168
- Local Institution - 0025
-
Koscian, Poland, 64-000
- Local Institution - 0015
-
Krak, Poland, 31-637
- Local Institution - 0018
-
Krakow, Poland, 30-363
- Local Institution - 0014
-
Krakow, Poland, 31-011
- Centrum Nowoczesnych Terapii Dobry Lekarz Spolka z ograniczona odpowiedzialnoscia
-
Lublin, Poland, 20-607
- Local Institution - 0016
-
Poznan, Poland, 60-218
- Local Institution - 0024
-
Sosnowiec, Poland, 41-200
- Local Institution - 0029
-
Warsaw, Poland, 02-172
- Local Institution - 0019
-
Warszawa, Poland, 02-691
- Local Institution - 0022
-
Wroclaw, Poland, 50-363
- Local Institution - 0010
-
Wroclaw, Poland, 52-416
- Local Institution - 0023
-
-
-
-
-
Brasov, Romania, 500283
- Local Institution - 0033
-
Galati, Romania, 800578
- Local Institution - 0004
-
Ramnicu Valcea, Romania, 240277
- Local Institution - 0002
-
-
-
-
-
Ekaterinburg, Russian Federation, 620043
- Local Institution - 0061
-
Kemerovo, Russian Federation, 650066
- Local Institution - 0056
-
Novosibirsk, Russian Federation, 630099
- Local Institution - 0072
-
Orenburg, Russian Federation, 460018
- Local Institution - 0057
-
Saint - Petersburg, Russian Federation, 191045
- Local Institution - 0062
-
Smolensk, Russian Federation, 214025
- Local Institution - 0070
-
St. Petersburg, Russian Federation, 197341
- Local Institution - 0058
-
Vladimir, Russian Federation, 600005
- Local Institution - 0055
-
Yaroslavl, Russian Federation, 150023
- Local Institution - 0068
-
Yaroslavl, Russian Federation, 150030
- Local Institution - 0060
-
-
-
-
-
Malaga, Spain, 29010
- Hospital Regional Universitario de Malaga Hospital General
-
Sabadell, Spain, 08208
- Local Institution - 0138
-
Sevilla, Spain, 41014
- Local Institution - 0124
-
-
-
-
-
Taichung, Taiwan, 40201
- Local Institution - 0052
-
Taipei, Taiwan, 10002
- Local Institution - 0051
-
Taipei, Taiwan, 110
- Local Institution - 0137
-
Taipei City, Taiwan, 10630
- Local Institution
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233-1913
- Local Institution - 0077
-
-
California
-
El Cajon, California, United States, 92020
- Local Institution - 0030
-
Torrance, California, United States, 90502
- Local Institution - 0049
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Local Institution - 0074
-
-
Florida
-
Aventura, Florida, United States, 33180
- Local Institution - 0115
-
Brandon, Florida, United States, 33511
- Local Institution - 0044
-
Gainesville, Florida, United States, 32603
- Local Institution - 0140
-
Orlando, Florida, United States, 32835
- Local Institution - 0133
-
Ormond Beach, Florida, United States, 32174-1139
- Local Institution - 0032
-
Tampa, Florida, United States, 33613
- Local Institution - 0048
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Local Institution - 0094
-
Lawrenceville, Georgia, United States, 30046
- Local Institution - 0050
-
-
New York
-
Brooklyn, New York, United States, 11201
- Local Institution - 0123
-
New York, New York, United States, 10016
- Local Institution - 0131
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7280
- Local Institution - 0071
-
Charlotte, North Carolina, United States, 28204
- Local Institution - 0031
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Local Institution - 0064
-
-
Pennsylvania
-
Wyomissing, Pennsylvania, United States, 19610
- Local Institution - 0035
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Local Institution - 0121
-
-
Tennessee
-
Jackson, Tennessee, United States, 38305
- Local Institution - 0001
-
-
Texas
-
Austin, Texas, United States, 78745
- Tekton Research - Austin
-
Austin, Texas, United States, 78731-3146
- Local Institution - 0041
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Houston, Texas, United States, 77084
- Local Institution - 0037
-
Mesquite, Texas, United States, 75150
- Local Institution - 0046
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Completion of SLE Study (NCT03252587) through the protocol-required treatment period, and currently receiving blinded study drug. Note: If a subject is not receiving blinded study drug due to exceptional circumstances (eg, missed investigational product [IP] due to COVID-19 pandemic, delays in study approval, etc), the subject may be allowed to enroll with approval from the BMS Clinical Trial Physician or designee.
Exclusion Criteria:
- Any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or considered unsuitable by the investigator for any other reason
- Evidence of active tuberculosis (TB)
Other protocol-defined inclusion/exclusion criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BMS-986165 Dose 1
|
Specified dose on specified days
Other Names:
|
Experimental: BMS-986165 Dose 2
|
Specified dose on specified days
Other Names:
|
Experimental: BMS-986165 Dose 3
|
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with Adverse Events (AEs)
Time Frame: Up to 30 days after last treatment dose (approximately 178 weeks)
|
Up to 30 days after last treatment dose (approximately 178 weeks)
|
Number of participants with Serious Adverse Events (SAEs)
Time Frame: Up to 30 days after last treatment dose (approximately 178 weeks)
|
Up to 30 days after last treatment dose (approximately 178 weeks)
|
Number of participants with AEs leading to discontinuation
Time Frame: Up to 30 days after last treatment dose (approximately 178 weeks)
|
Up to 30 days after last treatment dose (approximately 178 weeks)
|
Number of participants with abnormal change from baseline in laboratory measurements over time
Time Frame: Up to 30 days after last treatment dose (approximately 178 weeks)
|
Up to 30 days after last treatment dose (approximately 178 weeks)
|
Number of participants with abnormal change from baseline in vital signs over time
Time Frame: Up to 30 days after last treatment dose (approximately 178 weeks)
|
Up to 30 days after last treatment dose (approximately 178 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 26, 2019
Primary Completion (Estimated)
March 31, 2025
Study Completion (Estimated)
March 31, 2025
Study Registration Dates
First Submitted
March 27, 2019
First Submitted That Met QC Criteria
April 16, 2019
First Posted (Actual)
April 18, 2019
Study Record Updates
Last Update Posted (Estimated)
December 20, 2023
Last Update Submitted That Met QC Criteria
December 19, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IM011-074
- 2018-003471-35 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on BMS-986165
-
Bristol-Myers SquibbCompletedSystemic Lupus Erythematosus | Inflammatory Bowel Diseases | Psoriasis | Arthritic PsoriasisUnited States
-
Bristol-Myers SquibbCompletedActive Psoriatic ArthritisSpain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
-
Bristol-Myers SquibbCompletedHealthy ParticipantsUnited States
-
Bristol-Myers SquibbCompletedHealthy ParticipantsUnited States
-
Bristol-Myers SquibbCompletedPsoriasisUnited States, Germany, Australia, Canada, Japan, Latvia, Mexico, Poland
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedHealthy VolunteersUnited Kingdom
-
Bristol-Myers SquibbCompleted
-
Mayo ClinicBristol-Myers SquibbRecruiting
-
Bristol-Myers SquibbCompletedSystemic Lupus ErythematosusTaiwan, United States, Hungary, Argentina, Canada, Spain, Japan, Poland, Russian Federation, Korea, Republic of, Israel, Romania, Mexico, Australia, Brazil, Colombia, Germany